Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).
from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J
source https://techncruncher.blogspot.com/2021/10/osimertinib-offers-hint-of-added.html
samedi 2 octobre 2021
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy
Inscription à :
Publier les commentaires (Atom)
Aucun commentaire:
Enregistrer un commentaire